These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18047739)

  • 1. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
    Davies JE; Sarkar S; Rubinsztein DC
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S2. PubMed ID: 18047739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patented small molecule inhibitors in the ubiquitin proteasome system.
    Guédat P; Colland F
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S14. PubMed ID: 18047738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting.
    Nury D; Doucet C; Coux O
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S7. PubMed ID: 18047744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
    Hunter JM; Lesort M; Johnson GV
    J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice.
    Wang J; Wang CE; Orr A; Tydlacka S; Li SH; Li XJ
    J Cell Biol; 2008 Mar; 180(6):1177-89. PubMed ID: 18362179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes.
    Cardozo T; Pagano M
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S9. PubMed ID: 18047746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ubiquitin system, disease, and drug discovery.
    Petroski MD
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S7. PubMed ID: 19007437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Ubiquitin Proteasome Pathway with Traditional Chinese Medicine for Treatment of Spinocerebellar Ataxia Type 3.
    Chen IC; Chang CN; Chen WL; Lin TH; Chao CY; Lin CH; Lin HY; Cheng ML; Chiang MC; Lin JY; Wu YR; Lee-Chen GJ; Chen CM
    Am J Chin Med; 2019; 47(1):63-95. PubMed ID: 30612452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the ubiquitin proteasome system in renal cell carcinoma.
    Corn PG
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S4. PubMed ID: 18047741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the ubiquitin proteasome system in Alzheimer's disease.
    Upadhya SC; Hegde AN
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S12. PubMed ID: 18047736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the ubiquitin proteasome system in Parkinson's disease.
    Lim KL; Tan JM
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S13. PubMed ID: 18047737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.
    Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H
    Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the ubiquitin-proteasome system impaired in Huntington's disease?
    Ortega Z; Díaz-Hernández M; Lucas JJ
    Cell Mol Life Sci; 2007 Sep; 64(17):2245-57. PubMed ID: 17604996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
    Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
    FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the UPS as therapy in multiple myeloma.
    Chauhan D; Bianchi G; Anderson KC
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S1. PubMed ID: 19007431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin domain proteins in disease.
    Madsen L; Schulze A; Seeger M; Hartmann-Petersen R
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S1. PubMed ID: 18047733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of polyglutamine disorders: aggregation revisited.
    Michalik A; Van Broeckhoven C
    Hum Mol Genet; 2003 Oct; 12 Spec No 2():R173-86. PubMed ID: 14504263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UPS: a promising target for breast cancer treatment.
    Sato K; Rajendra E; Ohta T
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S2. PubMed ID: 19007432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
    Bowman AB; Yoo SY; Dantuma NP; Zoghbi HY
    Hum Mol Genet; 2005 Mar; 14(5):679-91. PubMed ID: 15661755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's disease: from pathology and genetics to potential therapies.
    Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
    Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.